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During the 12th International Workshop on Autoantibodies and Autoimmunity held in
Sao Paulo, Brazil, on August 28, 2014, a full day session was devoted to establishing
a consensus on the nomenclature of staining patterns observed in the antinuclear
antibody (ANA) indirect immunofluorescence test on HEp-2 cells. The current report
summarizes the collective agreements with input from the host Brazilian and international
communities that represented research, clinical, and diagnostic service laboratories.
Patterns are categorized in three major groups (nuclear, cytoplasmic, and mitotic
patterns) and each pattern has been defined and described in detail. The consensus
nomenclature and representative patterns are made available online at the international
consensus on antinuclear antibody pattern (ICAP) website (www.ANApatterns.org).
To facilitate continuous improvement and input, specific comments on ICAP are
encouraged and these will be discussed in subsequent ICAP meetings. The ultimate
goal with the establishment of the ICAP is to promote harmonization and understanding
of autoantibody test nomenclature, as well as interpretation guidelines for ANA testing,
thereby optimizing usage in patient care.
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Introduction
The antinuclear antibody (ANA) assay is commonly used as
a laboratory indicator for the body’s autoimmune response (1,
2). Since the 1970s, HEp-2 cells have been increasingly used
and were eventually adopted as the universal standard substrate
in practically all commercially available ANA assay kits. There
have been many continuing efforts to standardize ANA tests
and one significant accomplishment was the development of
autoantibody reference reagents (3). Over the past 25 years, the
Autoantibody Standardization Committee, a subcommittee of the
International Union of Immunological Societies (IUIS) Quality
Assessment and Standardization Committee, has collaborated
with the Centers for Disease Control and Prevention (CDC)
and other agencies to provide autoantibody reference standards
(also known as CDC ANA reference standards, or IUIS ANA
reference standards). To date, there are 17 reference standards
available free of charge to all qualified clinical or commercial
laboratories and research investigators. The overall goal is to pro-
mote laboratory quality control of ANA and related autoantibody
testing (4). However, the lack of inter-laboratory standardiza-
tion and other problems in ANA testing and reporting persist,
leading to recent discussions on the appropriate use of the ANA
assay (5–7).
During the 12th International Workshop on Autoantibodies
and Autoimmunity (IWAA) held in São Paulo, Brazil, a full
day session attended by 66 experts was devoted to establishing
an International Consensus on ANA staining Patterns (ICAP).
Brazil has a long history of ANA pattern consensus with their
first workshop held in Goiania in August, 2000. Their first
consensus report was published in 2001 (8) and two subse-
quent ANA consensus reports published in 2003 (9) and 2009
(10). These earlier publications were in Portuguese with some
including English abstracts. The report for the fourth Brazil-
ian ANA consensus meeting in 2013 was published entirely
in English (11). Other reports with a focus on nomencla-
ture/consensus in ANA on HEp-2 cells are acknowledged and
were referred to during the ICAP meeting and writing of this
report (12–15).
This report summarizes the ICAP working consensus and this
is also available online at the IWAA 2014 website with a link to
a permanent website: www.ANApatterns.org. The ultimate goal
with the implementation of ICAP is to promote harmonization
of autoantibody test nomenclature and interpretation, and to
maximize usages in patient care.
Abbreviations: AC, anti-cell; AIH, autoimmune hepatitis; ALD, alcoholic liver
disease; AMA, anti-mitochondrial antibodies; ANA, antinuclear antibody; CDC,
Centers for Disease Control and Prevention; CENP-F, centromere-associated pro-
tein F; CLD, chronic liver diseases; DFS, dense fine speckled; DM, dermatomyositis;
EBV, Epstein–Barr virus; HCV, hepatitis C virus; HIV, human immunodeficiency
virus; IIF, indirect immunofluorescence; IMPDH2, inosine monophosphate dehy-
drogenase 2; IUIS, International Union of Immunological Societies; MCTD, mixed
connective tissue disease; NE, nuclear envelope; NHS, normal human serum; NOR,
nucleolar organizer regions; PBC, primary biliary cirrhosis; PCNA, proliferating cell
nuclear antigen; PM, polymyositis; RNP, ribonucleoprotein; RR, rods and rings;
SARD, systemic autoimmune rheumatic diseases; SjS, Sjögren’s syndrome; SLE,
systemic lupus erythematosus; SSc, systemic sclerosis.
Methods in Establishing Consensus
The critical need for the ICAP initiative was discussed and con-
ceived during the planning stages of the IWAA meeting to be
held in São Paulo. A full day agenda was designed for the ICAP
initiative based on four initial discussion sessions that would focus
on nuclear, nucleolar, cytoplasmic, and mitotic and complex pat-
terns, respectively. This was followed by general discussion toward
building a consensus and presentation of the findings to the wider
IWAA conference forum. Two discussion leaders were selected
for each session based in part on their expertise. Nuclear patterns
were coordinated by Karsten Conrad (Germany) and Jan Damoi-
seaux (Netherlands). Nucleolar patterns were coordinated by
Minoru Satoh (Japan) and Orlando Gabriel Carballo (Argentina).
Cytoplasmic patterns were coordinated by Edward K. L. Chan
(USA) and Carlos A. von Mühlen (Brazil). Mitotic and complex
patterns were coordinated by Tsuneyo Mimori (Japan) and Man-
fred Herold (Austria). An additional 1-h session was devoted to
technical recommendations presented by Ignacio Garcia-De La
Torre (Mexico) andPaulo LuizCarvalho Francescantonio (Brazil).
Prior to the IWAAmeeting, information regarding the relevant
literature on ANA consensus was provided to all discussion lead-
ers. Each pair of coordinators was tasked to lead the assigned topic
for discussion. This included collecting and organizing relevant
ANA patterns into a proposed preliminary consensus. During
the ICAP sessions, 66 registrants (Table S1 in Supplementary
Material) representing 15 countries (Table S2 in Supplementary
Material) attended the presentations by the discussion leaders
and about two-thirds participated in the concluding question and
answer sessions. Briefly, one or both of the discussion leaders
presented an outline of the logic model classification tree that
would be useful to differentiate staining patterns. Examples of
each staining pattern were displayed and opened for discussion,
and patterns that attained initial consensus were established and
separated from others in need of further discussion. At the end
of the day, an additional discussion session took place to plan
for a final report to be presented as the summary of the first
ICAP. It was agreed that deliberations on the major technical
considerations of ANA immunoassays would be summarized in
a separate report to follow the current manuscript. In addition,
it was determined that the present report needed to be in place
in the following months to ensure that a summation of the ICAP
deliberations would be made available in a timely manner. Finally,
it was established that a website would be constructed under the
leadership of Wilson de Melo Cruvinel and Edward K. L. Chan
with input and consultation with all participants as needed. The
website would display the reference images for ongoing discussion
by the leaders, thereby consolidating the consensus on the ANA
patterns and nomenclature. In due time, the website will display
the classification tree of the ANA patterns and representative
images of each pattern. The primary goal of the website is to
provide free access to the consensus patterns by the international
community. There was agreement that ongoing efforts would
be made to further improve guidelines by means of successive
rounds of ICAP. The second ICAPmeeting has been scheduled to
take place on September 22, 2015, immediately prior to the 12th
Dresden Symposium on Autoantibodies in Germany.
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Classification Tree
Antinuclear antibody is the common clinical and laboratory term
used for more than 50 years. However, the name “antinuclear” for
the ANA test does not take into consideration that autoantibodies
to cell compartments other than the nucleus are also detected.
Nevertheless, the ANA term is maintained for historical reasons
and also for laboratory coding and invoicing. Thus, in situations
when there is clear cytoplasmic ormitotic apparatus reactivity, the
ANA indirect immunofluorescence (IIF) test is to be reported as
positive. The classification tree for most staining patterns is pre-
sented in Figure 1 and they are segregated into nuclear, cytoplas-
mic, and mitotic patterns. In accord with the Brazilian Consensus
strategy (11), certain patterns are recommended for mandatory
reporting, while others are for expert-level reporting. During the
write-up of this manuscript, in addition to comments from the
reviewers, there were some concerns that “mandatory” might not
fit well with dictating the requirements for clinical immunol-
ogy laboratories, especially in an international setting. The ICAP
intention is to indicate patterns that should be readily recognized
(competent-level) versus patterns that would be more challenging
and distinguishable only when observers or technologists have
attained the expert-level. The distinction between competent-level
versus expert-level patterns is based on at least two considerations.
First, clinical relevance probably is amajor consideration to ensure
that important clinical implications are recognized. Second, easily
recognizable patterns should be included even when the clinical
relevance is less clear at this time. It is acknowledged that the
current separation of competent-level patterns (amber boxes) and
expert-level patterns (olive green boxes) is a temporary status
that may change over time. However, competent-level patterns
are strongly recommended for reporting. The competent-level
patterns are placed at the top levels starting from the left. Each
pattern is assigned a code below the descriptor. For example, the
nuclear homogeneous box has the code anti-cell pattern 1 (AC-
1). These codes allow for easy and objective access and reference
to the web-based consensus patterns available on the ICAP web-
site (www.ANApatterns.org). The assignment of the different AC
codes generally flows from left to right, and top to bottom. Thus,
the classification tree shows 11 competent-level reportable pat-
terns. The six competent-level reportable nuclear patterns include
homogeneous, speckled, dense fine speckled, centromere, discrete
nuclear dots, and nucleolar. Five competent-level reportable cyto-
plasmic patterns are fibrillar, speckled, reticular/mitochondrion-
like, polar/Golgi-like, and rods and rings (RR). The RR pattern
is not recognized in certain commercial ANA substrates as these
structures are only seen consistently in slides from some man-
ufacturers (16–18). It is acknowledged that not all known ANA
patterns are shown in Figure 1 and that new editions of the ICAP
may add new patterns to this consensus classification tree. For
example, mixed patterns that may originate from a mixture of
one or more simple patterns are commonly observed but it was
FIGURE 1 | Nomenclature and classification tree for nuclear, nucleolar,
cytoplasmic, and mitotic IIF staining patterns on HEp-2 cell substrates.
This is a summary of the International Consensus on Antinuclear antibody
Pattern (ICAP) meeting and subsequent discussion, debate, and dialog.
Patterns are shown from AC-1 to AC-28. Examples of some of the major
patterns are shown in Figures 2 and 3, while additional images of each are
depicted in a web page linked to the ANA ICAP website
(www.ANApatterns.org). Boxes with amber background are recommended as
competent-level reporting, whereas those with olive green background are
considered for expert-level reporting. AC, anti-cell.
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TABLE 1 | Nuclear patterns defined by reactivity with distinct nuclear compartments in interphase cells and staining of mitotic cells.
Nucleoplasm Nucleoli Metaphase
chromosomal
plate
Metaphase
cytoplasm
Mitotic
apparatus
Interphase
cytoplasm
Homogeneous (AC-1) Homogeneous Negative/positive Homogeneous Negative Negative Negative
Speckled
Dense fine speckled
(AC-2)
Heterogeneous fine
speckles
Negative Heterogeneous fine
speckles
Negative Negative Negative
Fine speckled (AC-4) Uniform fine speckles Negative/positive Negative Diffuse fine speckles Negative Negative
Large/coarse speckled
(AC-5)
Variably sized large
speckles
Negative Negative Diffuse fine speckles Negative Negative
Discrete nuclear dots
Centromere (AC-3) ~30–50 dots Negative ~30–50 aligned dots Negative Negative Negative
Multiple nuclear dots
(AC-6)
~10 dots Negative Rarely occasional dots Negative/positive Negative Negative
Few nuclear dots (AC-7) 1–6 dots Negative Rarely occasional dots Negative Negative Negative
Nucleolar
Homogeneous (AC-8) Negative Homogeneous Negative Diffuse homogeneous Negative Negative
Clumpy (AC-9) Negative Large granular Positive
(peri-chromosomal)
Negative/positive Negative Negative
Punctate (AC-10) Negative Fine speckled 1–5 bright pairs of
spots (NOR)
Negative/positive Negative Negative
Nuclear envelope
Smooth NE (AC-11) Linear staining of NE Negative Negative Diffuse Negative Negative
Punctate NE (AC-12) Granular staining of NE Negative Negative Homogeneous/dense
speckled
Negative Negative
Pleomorphic
PCNA-like (AC-13) Variably sized speckles in
S-phase cells (~30%)
Positive in late
S-phase
Negative Negative Negative Negative
CENP-F-like (AC-14) Fine granular in G2-phase Negative ~30–50 aligned dots Diffuse Midbody Negative
Amber background are recommended as competent-level reporting, whereas all others (Olive green) are considered for expert-level reporting.
decided that theywould not be included in the first iteration of this
exercise. One point that did not reach consensus was the proposal
to develop a separate category of “composite patterns,” such as
those in which single autoantibody specificity yields a combi-
nation of staining of different cell compartments (e.g., NuMA,
topoisomerase I).
Nuclear Patterns
Nuclear patterns are defined as any staining of the HEp-2 inter-
phase nuclei, irrespective of positive or negative staining ofmitotic
cells. In total, 6 major pattern groups (top row under nuclear
patterns, Figure 1) and 11 minor pattern subgroups can be rec-
ognized based on the staining of distinct nuclear compartments
in interphase cells (Table 1). Representative images of the major
patterns are shown in Figure 2. The respective nomenclature is
primarily based on the reactivity observed in the nucleoplasm (cf.
homogeneous or speckled) and the nuclear subcomponents that are
recognized (cf. centromere or nucleolar). Homogeneous, Speckled,
Centromere, and Nucleolar are major pattern groups considered
as competent-level report for all laboratories that perform ANA
IIF tests. If there is a very strong correlation of the IIF pattern with
the target autoantigen that is recognized, the common name of
the respective antigen is used with addition of “-like” (cf. PCNA-
like). It should be noted that the use of the term “-like” to describe
patterns is that the observation of the pattern itself should rarely
be taken as the ultimate determination of the autoantibody speci-
ficity. Instead, further characterization is recommended includ-
ing co-localization with known marker antibodies, Western blot,
immunoprecipitation, double immunodiffusion, ELISA, dot or
line blots, chemiluminescence, or other solid phase immunoas-
says. Synonyms based on historical nomenclature of the distinct
patterns are listed in Table 2. This table also includes associations
of the distinct patterns with the autoantigen specificity (when
known) as well as diseases.
Homogeneous
The homogeneous nucleoplasmic staining is the first major group
of nuclear patterns that is considered competent-level in terms
of recognition and reporting. It is characterized by a diffuse and
uniform staining (Figure 2A). The nucleolar region usually is
also stained, but occasionally may not show any staining. High
titer sera may show more pronounced staining at the outer rim
of interphase nuclei. The chromatin plate of metaphase cells also
shows homogeneous staining, with a clearly hyaline, or diffuse,
appearance. The cytoplasm is typically negative in interphase and
mitotic cells. The homogeneous pattern is associated with anti-
bodies directed to chromatin components, such as dsDNA, core
histones, and/or nucleosomes. It is of utmost importance that the
homogeneous pattern should be differentiated from the dense fine
speckled (DFS) pattern in routine practice since the clinical signif-
icance of both patterns is quite different (see next paragraph).
Speckled
The speckled nuclear pattern is a major group that is to be rec-
ognized and reported by all clinical laboratories. The distinction
of a fine or large/coarse speckled pattern, based on the size of the
speckles in interphase cells, is only recommended for expert-level
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FIGURE 2 | Representative images of selected major HEp-2 cell patterns. (A) homogeneous nuclear (AC-1); (B) nuclear dense fine speckled (AC-2);
(C) centromere (AC-3); (D) homogeneous nucleolar (AC-8); (E) cytoplasmic fibrillar linear (AC-15); (F) cytoplasmic discrete dots (AC-18); (G) polar/Golgi-like (AC-22);
(H) rods and rings (AC-23).
laboratories. The distinctive feature of the speckled pattern is
the granular staining of the nucleoplasm of interphase cells. The
large/coarse speckled pattern is characterized by dense interme-
diate sized speckles in the nucleus associated with larger speck-
les throughout the nucleoplasm of interphase cells. Typically,
both nucleoli and mitotic chromatin show no staining. The fine
speckled pattern shows a fine granular, sometimes very dense,
staining of the nucleus in a uniform distribution. Nucleoli may
stain (e.g., SS-B/La or Ku antibodies) or are negative. The chro-
matin plate is usually negative with some exceptions, like DNA
topoisomerase I antibodies. The cytoplasm of metaphase cells of
both large and fine speckled nuclear patterns reveals a speckled
pattern that may be more condensed around the chromatin plate;
however, this characteristic is not critical in defining this pat-
tern. A key challenge, though, is to distinguish the DFS pattern
from both the homogeneous and the speckled pattern. The DFS
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TABLE 2 | Synonyms for nuclear patterns and association with specific antigens and diseases.
Synonyms Antigen associations Disease association
Nu
cle
ar
pa
tte
rn
s
Homogeneous (AC-1) Diffuse dsDNA, nucleosomes, histones SLE, drug-induced lupus, juvenile
idiopathic arthritis
Speckled (AC-2,4,5) Granular hnRNP, U1RNP, Sm, SS-A/Ro (Ro60),
SS-B/La, RNA polymerase III, Mi-2, Ku
MCTD, SLE, SjS, DM, SSc/PM overlap
Dense fine speckled (AC-2) None DFS70/LEDGF Rare in SLE, SjS, SSc
Fine speckled (AC-4) Fine granular SS-A/Ro (Ro60), SS-B/La, Mi-2, TIF1γ, TIF1β,
Ku, RNA helicase A, Replication protein A
SjS, SLE, DM, SSc/PM overlap
Large/coarse speckled (AC-5) Spliceosome/nuclear matrix hnRNP, U1RNP, Sm, RNA polymerase III MCTD, SLE, SSc
Discrete nuclear dots
Centromere (AC-3) Kinetochore CENP-A/B (C) Limited cutaneous SSc, PBC
Multiple nuclear dots (AC-6) 6–20 nuclear dots, NSpI,
PML bodies
Sp100, PML proteins, MJ/NXP-2 PBC, SARD, PM/DM
Few nuclear dots (AC-7) 1–6 nuclear dots, Cajal
bodies (coiled body)
p80-coilin, SMN SjS, SLE, SSc, PM, asymptomatic
individuals
Nucleolar (AC-8,9,10)
Homogeneous (AC-8) None PM/Scl-75, PM/Scl-100, Th/To,
B23/nucleophosmin, nucleolin, No55/SC65
SSc, SSc/PM overlap
Clumpy (AC-9) None U3-snoRNP/fibrillarin SSc
Punctate (AC-10) Nucleolar speckled RNA polymerase I, hUBF/NOR-90 SSc, SjS
Nuclear envelope (AC-11,12)
Smooth nuclear envelope
(AC-11)
Nuclear rim, nuclear
membrane, membranous
Lamins A,B,C, or lamin-associated proteins SLE, SjS, seronegative arthritis
Punctate nuclear envelope
(AC-12)
Nuclear membrane pores Nuclear pore complex proteins (i.e., gp22) PBC
Pleomorphic (AC-13,14)
PCNA-like (AC-13) None PCNA SLE, other conditions
CENP-F-like (AC-14) MSA-3, NSp-II CENP-F Cancer, other conditions
These disease associations are primarily based on the target antigens recognized by autoantibodies that reveal a particular ANA pattern. Amber background are recommended as
competent-level reporting, whereas all others (Olive green) are considered for expert-level reporting.
pattern is characterized by a unique dense and heterogeneous
speckled staining of both the nucleoplasm of interphase cells and,
in contrast with most other speckled patterns, the metaphase
chromosomal plate (Figure 2B). One distinctive peculiarity of this
speckled pattern is heterogeneity of the size, brightness, and den-
sity of the speckles throughout the interphase nucleoplasm (19,
20). This composite pattern is considered clinically relevant since
it indicates that the presence of SLE, SjS, or SSc is unlikely (19, 21–
24). Therefore, the DFS pattern is classified for competent-level
reporting.
Centromere and Discrete Nuclear Dots
The centromere pattern is considered a subset of the discrete
nuclear dots patterns (Figure 2C). Thismost characteristic pattern
is to be recognized and reported by all clinical laboratories and,
therefore, placed at the same level as homogeneous and speckled.
In the classification tree, the discrete nuclear dots box is overlap-
ping with centromere to symbolize their relationship – that they
are both discrete nuclear dots and yet readily distinguishable and
with different clinical associations. The centromere pattern shows
multiple, somewhat uniform, discrete dots distributed throughout
the entire nucleus. Mitotic cells also exhibit this speckled/dot
pattern in a typical alignment within the condensed chromosomal
material. The nucleoli are usually negative, although sometimes
some dots may cluster within the nucleolar area. Antibodies
revealing this pattern react with proteins localized to the kineto-
chores of chromosomes.
The remaining discrete nuclear dot patterns are subdivided
based on the number and localization of the dots in the nuclei
of interphase cells. The multiple nuclear dot pattern character-
istically reveals on average 10 discrete dots (often range from 6
to 20 dots), variable in size, in the nucleus of interphase cells.
The chromosomal plates of mitotic cells do not typically stain,
but cytoplasmic staining may be observed. These nuclear dots
are known as promyelocytic leukemia (PML) nuclear bodies (25,
26). Some of the associated antigens include PML proteins, such
as Sp100 (26), and the more recently described MJ/NXP-2 anti-
gen (27). The few nuclear dots pattern shows only 1–6 dots per
nucleus, often in close proximity to nucleoli. Cells with higher
number of dots (4–6) are in the late S/G2 phase of the cell cycle
(28); metaphase chromatin in mitotic cells is usually negative.
These nuclear dots are Cajal bodies (formerly known as coiled
bodies) and the primary antigen is p80-coilin (29) and survival
of motor neuron (SMN) (30).
Nucleolar
Nuclear staining that is predominantly restricted to the nucleoli
of interphase cells is referred to as the nucleolar pattern. This
pattern is considered as competent-level reporting for clinical
laboratories. Based on the staining pattern within the nucleoli,
three subtypes may be distinguished in expert-level laboratories.
The homogeneous nucleolar pattern is characterized as diffuse
staining of the entire nucleolus and may present a relatively much
weaker diffuse staining of the nucleoplasm, while the cytoplasm
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of mitotic cells tends to be diffusely stained (Figure 2D). Irreg-
ular staining of the nucleoli, revealing clustered large granules, is
referred to as clumpynucleolar pattern. The classical autoantibody
specificity associatedwith this clumpy nucleolar pattern is anti-U3
RNP/fibrillarin, which is also known to stain Cajal bodies (31).
In mitotic cells, the outer surface of the condensed chromatin
is often stained, while the cytoplasm of mitotic cells may be
weakly positive. The punctate nucleolar pattern is characterized by
densely distributed but distinct dots in the nucleoli of interphase
cells. In metaphase cells, up to five bright pairs of the nucleolar
organizer regions (NOR) can be seen as bright discrete dots within
the chromatin mass. The cytoplasm of mitotic cells may show
weak diffuse staining.
Nuclear Envelope
Staining of the nuclear envelope (NE)may reveal either a continu-
ous linear or punctate staining of interphase cells, i.e., smooth NE
or punctate NE. In metaphase cells, the fluorescence is diffusely
localized throughout the cytoplasm, leaving the metaphase plate
unstained. Although both the major nuclear category and both
subgroups are considered expert-level reporting for all clinical
laboratories, this reactivity is considered to be a definable ANA
pattern with a limited repertoire of autoantibody specificities and
their respective clinical significance.
Pleomorphic
Both the proliferating cell nuclear antigen (PCNA) pattern and
the CENP-F pattern are considered subtypes of the pleomorphic
nuclear staining category, because they show variable staining
characteristics at distinct stages of the cell cycle. Neither the gen-
eral pleomorphic pattern nor the subtypes are to be reported by all
clinical laboratories. However, these patterns are to be reported as
nuclear pattern ANA positive.
The PCNA-like staining pattern is characterized by variable
sized speckles in the nucleoplasm, which achieves maximum
intensity and density of speckles in the S-phase of cell cycle.
Depending on the HEp-2 cell growth characteristics and slide
preparation, this is represented in about 30% of theHEp-2 cells. In
late S-phase and earlyG2 phase, the speckles become progressively
sparser and the nucleoli are also stained. G1 cells and metaphase
cells typically do not stain.
On the other hand, the CENP-F-like pattern shows fine gran-
ular staining of the nucleoplasm, but not the nucleoli of inter-
phase cells. There is striking variability in intensity with the
strongest staining in G2 phase and weakest/negative staining
in G1. Centromere staining is seen only in prometaphase and
metaphase cells, revealing multiple aligned small and faint dots.
Prometaphase cells frequently show a weak staining of the nuclear
envelope. The surrounding cytoplasm of the mitotic cells is typ-
ically diffusely stained. While some anti-CENP-F sera also show
staining of the midbody, this is not a constant feature associated
with anti-CENP-F.
Proliferating cell nuclear antigen and CENP-F staining pat-
terns are labeled as PCNA-like and CENP-F-like for the obvious
reason that their staining patterns are highly characteristic for
autoantibodies against the respective antigens. However, further
confirmatory testing is required for the definite determination of
each specificity.
Cytoplasmic Patterns
The classification tree for cytoplasmic patterns is also presented
in Figure 1 and representative images are shown in Figure 2.
Cytoplasmic patterns are defined as any staining of the HEp-2
cytoplasm, irrespective of positive or negative staining of nuclei
or mitotic cells. The five major pattern subgroups fibrillar, speck-
led, reticular/mitochondrion-like, polar/Golgi-like, and rods and
rings (RR) are considered competent-level reportable for labo-
ratories that perform ANA IIF tests. The nomenclature is pri-
marily based on the reactivity (staining characteristics) observed
in the cytoplasm (cf. fibrillar or speckled) and the cytoplasmic
structure that is recognized (cf. rods and rings). If there is a very
strong correlation with the target autoantigen or the intracellular
structure that is recognized, the name of the respective antigen
or intracellular structure is used with addition of “-like” (cf.
Golgi-like). Pattern associations with autoantigens and diseases
are summarized in Table 3.
Fibrillar Cytoplasmic
The fibrillar cytoplasmic patterns include linear, filamentous, and
segmental patterns. The fibrillar linear pattern is characterized by
decorated cytoskeletal fibers, sometimes with small, discontinu-
ous granular deposits. Target autoantigens include actin exhibit-
ing striated actin “cables” spanning the long axis of the cells. A
similar staining was reported for antibody to the heavy chain
of non-muscle myosin (32). The fibrillar filamentous pattern
describes filaments and fibrils spreading out from the nuclear
rim, often concentrated around the nucleus and extending into
the cytoplasm (Figure 2E). Typical antigens include vimentin and
cytokeratins. The fibrillar segmental pattern includes enhanced
decoration of short segments, periodic dense bodies, along the
stress fibers. Autoantigens include alpha-actinin, vinculin, and
tropomyosin.
Speckled Cytoplasmic
Within the major group of speckled cytoplasmic patterns, three
minor patterns can be distinguished. Several patterns with dis-
crete cytoplasmic dots have been described based on the num-
ber and distribution of dots in the cytoplasm. These patterns
have been categorized as the discrete dots/GW body-like pattern
(Figure 2F). Discrete, countable foci, known as GW bodies, are
irregularly distributed throughout the cytoplasm, although they
tend to be in closer proximity to the nuclear envelope (33).
Immuno-gold electron microscopy has demonstrated that they
range from 100 to 300 nm in diameter and are devoid of a lipid
bilayer membrane. GW bodies are small in early S phase and
larger during late S and G2 phases of the cell cycle. The major-
ity of GW bodies disassemble prior to mitosis and small GW
bodies reassemble in early G1. Known autoantigens within GW
bodies include Su/Argonaute-2, Ge-1, and GW182. Historically,
this staining pattern was thought to represent anti-lysosome anti-
bodies, but lysosomal target(s) displaying this staining pattern
have not been defined (34). Therefore, it may be that the lyso-
some nomenclature that appears in some publications is incorrect.
Other discrete cytoplasmic dots patterns include autoantibodies
staining early endosome antigen 1 (EEA1), and the cytoplasmic
linker protein, CLIP 170.
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TABLE 3 | Synonyms for cytoplasmic patterns and association with specific antigens and diseases.
Synonyms Antigen associations Disease association
Cy
to
pl
as
m
ic
pa
tte
rn
s
Fibrillar (AC-15,16,17)
Linear/actin (AC-15) Actin-like Actin, non-muscle myosin MCTD, chronic active hepatitis, liver cirrhosis, myasthenia
gravis, Crohn’s disease, PBC, long-term hemodialysis, rare in
SARD other than MCTD
Filamentous/
microtubules (AC-16)
Vimentin, cytokeratins Infectious or inflammatory conditions, long-term hemodialysis,
alcoholic liver disease, SARD, psoriasis, healthy controls
Segmental (AC-17) Alpha-actinin, vinculin, tropomyosin Myasthenia gravis, Crohn’s disease, ulcerative colitis
Speckled (AC-18–20)
Discrete dots (AC-18) GW body, processing
body, lysosome*
GW182, Su/Ago2, Ge-1 PBC, SARD, neurological and autoimmune conditions
Dense fine speckled
(AC-19)
Homogeneous PL-7, PL-12, ribosomal P proteins “anti-synthetase syndrome,” PM/DM, SLE, juvenile SLE,
neuropsychiatric SLE
Fine speckled (AC-20) Speckled Jo-1/histidyl-tRNA synthetase Anti-synthetase syndrome, PM/DM, limited SSc, idiopathic
pleural effusion
Reticular/AMA
(AC-21)
Mitochondrion-like PDC-E2/M2, BCOADC-E2, OGDC-E2,
E1α subunit of PDC, E3BP/protein X
Common in PBC, SSc, rare in other SARD
Polar/Golgi-like
(AC-22)
Giantin/macrogolgin, golgin-95/GM130,
golgin-160, golgin-97, golgin-245
Rare in SjS, SLE, RA, MCTD, GPA, idiopathic cerebellar ataxia,
paraneoplastic cerebellar degeneration, viral infections
Rods and rings
(AC-23)
IMPDH2, others HCV patients post-IFN/ribavirin therapy, rare in SLE,
Hashimoto’s and healthy controls
These disease associations are primarily based on the antigens recognized by antibodies that reveal this particular ANA pattern. Amber background are recommended as competent-level
reporting, whereas all others (Olive green) are considered for expert-level reporting.
*no molecular evidence to support this pattern is associated with lysosomal targets.
The cytoplasmic dense fine speckled/homogeneous pattern
appears as a cloudy, almost homogeneous, speckled pattern
throughout the cytoplasm and is sometimes referred to as homo-
geneous cytoplasmic. Autoantibodies associated with this pattern
include PL-7 or PL-12 in PM/DM, ribosomal P proteins in SLE,
in particular, juvenile and neuropsychiatric, and AIH. It should
be noted that this staining pattern is neither sensitive nor specific
for the autoantibodies directed to these targets.
In case of the cytoplasmic fine speckled/speckled pattern, small
speckles are scattered in the cytoplasmmostly with homogeneous
or dense fine speckled background. Possible autoantibodies are
against aminoacyl-tRNA-synthetases, mainly Jo-1 (histidyl-tRNA
synthetase). The main clinical associations are PM/DM and the
“anti-synthetase syndrome” (myositis, interstitial lung disease,
mechanics hands, arthritis, Raynaud’s phenomenon). There are
some concerns that this cytoplasmic fine speckled pattern may be
a pattern associationwith selectedHEp-2 substrates. Furtherwork
may be needed to validate putative antibody associations.
Reticular/Mitochondrion-Like (AMA)
The cytoplasmic reticular/mitochondrion-like pattern is repre-
sented as a characteristic coarse granular filamentous staining
extending from the nuclear envelope and tending to taper off
near the outer cytoplasm and cell membrane. The main autoanti-
gens are localized to the inner mitochondrial membrane and
consist of E2 components of the 2-oxoacid dehydrogenase fam-
ily of enzyme complexes (2-OACD), including pyruvate dehy-
drogenase complex (PDC-E2), branched chain 2-oxoacid dehy-
drogenase complex (BCOADC-E2), 2-oxo-glutarate dehydroge-
nase complex (OGDC-E2), the E1α subunit of PDC, and E3
binding protein (E3BP/protein X) (35). Anti-centromere, anti-
Sp100, antinuclear envelope, and anti-GWbody antibodies can be
occasionally observed togetherwith anti-mitochondria antibodies
(AMA). AMA and anti-Sp100 are highly associated with primary
biliary cirrhosis (PBC), and may precede the disease onset for
years and even decades. The presence of anti-centromere antibod-
ies is an indicator of current or evolving limited cutaneous SSc
and, in some patients, PBC may also develop during the clinical
course of the disease.
Polar/Golgi-Like
This pattern is characterized by a perinuclear arrangement of
coarse granules or lamellae on one pole of the cell corresponding
to the stacks of the Golgi complex (Figure 2G). Known autoanti-
gens recognized in this pattern are giantin/macrogolgin, golgin-
95/GM130, golgin-160, golgin-97, and golgin-245 (36, 37).
Rods and Rings
In HEp-2 cell ANA slides from certain manufacturers (16–18),
rods and rings (RR) structures present themselves in two major
forms, discrete filamentous “rods” 3–10mm in length, or annular
“rings” 2–5mm in diameter (38). Both forms are observed pri-
marily in the cytoplasm, although generally smaller structures are
regularly found in the nucleus under cellular conditions allowing
for RR formation. While it has been shown that RR are not asso-
ciated with any known organelles, perinuclear rods that appear
to wrap around or position along the cytoplasmic side of the
nuclear membrane have been observed (Figure 2H). Usually, 1–2
RR structures are observed in each cell. The major autoantigen
is inosine monophosphate dehydrogenase 2 (IMPDH2) the rate-
determining enzyme in the GTP biosynthetic pathway (38, 39).
The overwhelming clinical association is HCV under treatment
with α-interferon and ribavirin.
Mitotic Patterns
Patterns that address cell domains strongly related to mitosis are
classified as mitotic patterns (Figures 1 and 3). Some patterns that
Frontiers in Immunology | www.frontiersin.org August 2015 | Volume 6 | Article 4128
Chan et al. International consensus on ANA patterns
FIGURE 3 | Representative images of mitotic HEp-2 cell patterns. (A) centrosome (AC-24); (B) spindle fibers (AC-25); (C) NuMA-like (AC-26); (D) contractile
ring and intercellular bridge (AC-27).
TABLE 4 | Synonyms for mitotic patterns and association with specific antigens and diseases.
Synonyms Antigen associations Disease association
M
ito
tic
pa
tte
rn
s
Centrosome (AC-24) Centrioles Pericentrin, ninein,
Cep250, Cep110, enolase
Rare in SSc, Raynaud’s phenomenon, infections
(viral and mycoplasma)
Spindle fibers (AC-25) MSA-2 HsEg5 Rare in SjS, SLE, other SARD
NuMA-like (AC-26) MSA-1 Centrophilin SjS, SLE, other
Intercellular bridge
(AC-27)
Stem body, midbody Aurora kinase B, CENP-E,
MSA-2, KIF-14, MKLP-1
Rare in SSc, Raynaud’s phenomenon, malignancy
Mitotic chromosome
coat (AC-28)
Chromosome coat protein, dividing cell antigen,
mitotic chromosome autoantigen (MCA)
Modified histone H3,
MCA-1
Rare in discoid lupus erythematosus, chronic
lymphocytic leukemia, SjS, and polymyalgia
rheumatica
These disease associations are primarily based on the antigens recognized by antibodies that reveal this particular ANA pattern.
stain domains not exclusively associated with mitosis were clas-
sified as mitotic patterns if they exhibit very distinctive features
during mitosis. For example, centrosomes are easily recognized as
two bright spots in themitotic cell usually aligned at opposite sides
of themetaphase plate, but in the interphase cell a single less bright
and less specific spot is seen in the cytoplasm. Therefore, the cen-
trosome pattern was categorized as a mitotic pattern. The NuMA
pattern is characterized as strong and characteristic staining of the
pericentriolar region and themitotic spindle, but it also has a com-
pact speckled staining of interphase nuclei. Therefore, the NuMA
pattern was classified as a mitotic pattern. Pattern associations
with autoantigens and diseases are summarized in Table 4.
Centrosome
The pattern of antibodies against centrosome proteins imposes
most often in metaphase cells as two bright spots at the spindle
poles (Figure 3A). During the stages between prophase and
metaphase, two neighboring bright spots can be seen with
an increasing space gap as the mitotic cycle proceeds toward
metaphase. In interphase cells, one single spot in most cells is
visible relatively close to the nuclear envelope. Some interphase
cells, usually at G2 phase, may present a pair of adjacent dots.
Centrosomes are organelles located in the cytoplasm and con-
sisting of two orthogonally arranged centrioles embedded in an
amorphous mass of proteins. The term anti-centriole pattern has
been used synonymously. However, it was argued that the reac-
tivity is rarely restricted to the centrioles themselves. Therefore, it
was acknowledged that the term anti-centrosome is the preferred
term. The target autoantigens may be multiple components of
centrosome including enolase (40), pericentrin, PCM-1, ninein,
and Cep250 (41).
Spindle Fibers
Autoantibodies to spindle fibers have been reported in several
studies (42–45). In metaphase cells, a bright staining of the whole
spindle apparatus from the pole to the chromatin plate occurs.
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Fibers as well as centrosomes are stained, but not the chromosome
plate (Figure 3B). No consistent staining is seen in interphase
nuclei. In prophase cells, antibody binding may be first seen
as staining of centrosomes. Metaphase cells present a peculiar
fluorescence of the complete mitotic spindle apparatus which is
also seen in the anaphase. In telophase, a staining of the edges of
the intercellular bridge is observed. Some sera may occasionally
stain the midbody region as well. One target autoantigen is a
130-kDa protein termed HsEg5, a kinesin-like protein involved in
microtubule assembly of mitotic spindles (45).
The nuclear mitotic apparatus (NuMA) pattern, classified as
a subpattern of spindle fibers, cannot be identified on one sin-
gle cell but is a characteristic summary picture of many cells
in different stages of the cell cycle (Figure 3C). The nucleo-
plasm of interphase cells depicts a compact fine speckled pat-
tern, generally in high titer and sparing the nucleoli. Cells in
metaphase and anaphase show a strong staining of spindle poles
and the proximal parts of spindle fibers, also described as staining
of the triangular or banana-shaped pole area. The innermost
part of the centrosome remains unstained, yielding a ring-like
appearance. In telophase cells, no staining of the intercellular
bridge is seen, while the newly forming nuclei become diffusely
stained as telophase advances. The target antigen is a 210-kDa
centrophilin that is not only localized in the pericentrosomal
region of mitotic cells but also present in interphase nuclear
matrix (46).
Intercellular Bridge
The category intercellular bridge comprehends several distinct
patterns primarily affecting structures that refer to the latest
phases of mitosis, i.e., telophase and cytokinesis, localizations like
the cleavage furrow, the contractile ring, the midbody region,
and the stem body (Figure 3D). Most of these patterns yield no
consistent staining in the interphase cells but in prophase and
metaphase cells, fluorescence may be observed in the chromoso-
mal region and be seen as fine zipper-like streaks perpendicular
to the edge of the metaphase plate, representing the contractile
ring. In telophase cells, the staining is usually restricted to the
cleavage furrow with two bright spots at the boundary point
of both daughter cells (11). In interphase, namely the S and
G2 phase, cells may be stained with discrete or patchy nuclear
speckles (12).
The midbody is a mitotic domain that develops during the sep-
aration of the two daughter cells in cytokinesis. It originates from
the central spindle in anaphase and later midzone in telophase.
It was recommended (47) that the term midbody be used only
for patterns staining exclusively the midbody, i.e., the central
part within the bridge. The midbody is formed of more than
150 different constituents, structural proteins, and many motor
proteins (kinesins). Antibodies to kinesin 14 are characterized by
an exclusive staining of the midzone and the midbody. In the
center of themidbody, a bulge-like structure named the stem body
can be found (48).
The target antigens recognized by these autoantibodies have
not been completely identified, but aurora kinase B (49), an
enzyme involved in the attachment of the mitotic spindles to
centromeres, is a possible candidate. Several molecules, such
as CENP-E, MSA-2, KIF-14 and MKLP-1, are also reported as
midbody proteins (47).
Mitotic Chromosome Coat
Cells in pro- and metaphase show a fine granular staining of
the chromosomal surface. The inner part of condensed chromo-
somes remains unstained as well as the nucleoplasm of interphase
cells (47, 50, 51). However, since the autoantigens have not been
reported, the true prevalence of the autoantibody remains to be
determined. The inclusion of this pattern may stimulate further
investigations.
Discussion
The first Brazilian ANA consensus established a decision tree with
the focus on the morphological criteria for pattern recognition
and aimed to provide guidance for reading slides (8). The second
Brazilian ANA consensus extended the decision tree and added
some considerations for mixed patterns as well as the relevant
clinical associations for each pattern (9). The third ANA consen-
sus included new patterns and some recommendations for quality
controls (10). It was also proposed to exclude the use of trans-
fected HEp-2 cells (i.e., HEp-2000 substrate, ImmunoConcepts
Inc., Sacramento, CA, USA) for general pattern definition (10).
The more recent 2013 consensus added new patterns, such as
RR and CENP-F, and discussed the impact of automated ANA
screening (11). Building on the Brazilian experience, it was clear
that the first ICAP needed to limit its scope and plan to advance
this initial focus by establishing and publishing the consensus
of the assembled experts from wide geographic jurisdictions.
Accordingly, the primary goal of the first ICAP was to establish
a platform to promote and eventually reach a high level of con-
sensus. By proposing the preliminary nomenclature, classification
tree and a set of images for each autoantibody staining pattern
on the internet, we hope to stimulate discussion that will lead to
subsequent ICAP deliberations. Thus, the next rounds of ICAP
will successively lead to improvements in the nomenclature and
pattern identification based on the feedback, commentaries or
criticism from the international community.
Due to the nature of the consensus-building process, it is clearly
acknowledged that the first ICAP is incomplete and imperfect in
several aspects. One deficiency may be the lack of attention to
composite patterns and its distinction from mixed patterns. For
example, anti-topoisomerase I/Scl-70 often is associated with a
composite pattern but at this stage it has not been incorporated
in the classification tree for nuclear patterns. As in any other
ANA pattern, the autoantibody specificity should be confirmed
in additional specific testing. Yet, this first ICAP included another
composite pattern, namely the nuclear Dense Fine Speckled pat-
tern (AC-2), which has been strongly correlated to the presence
of autoantibody to DFS70 and, importantly, is seen in very low
frequency in SjS, SSc, and SLE (23, 24). Whether this pattern
can also be used for exclusion of other SARD remains to be
determined through systematic study of a wider range of diseases.
With respect to disease associations reported in Tables 2–4, it
should be noted that the ANA assay is primarily a screening
assay. Positive results of ANA screening tests should be titrated
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to end-point and further investigated with antigen-specific assays.
Thus, the disease associations listed in Tables 2–4 are primarily
based on the antigens recognized by their cognate autoantibodies
that reveal each particular ANA pattern; the disease associations
are not meant for inclusion in the test result in the report to
clinicians. It is acknowledged that the evidence for these clinical
associations varies widely ranging from single published reports
to multiple studies and readers are advised to consider each with
this reservation in mind.
Future attention should be devoted to clinically relevant mixed
patterns. A mixed pattern is defined when a patient has multiple
autoantibodies that recognize more than one simple pattern. For
example, in PBC, it is not uncommon to observe sera with autoan-
tibodies to both centromere and mitochondria or both multiple
nuclear dots and mitochondria. Since the centromere pattern has
discrete nuclear dots in the interphase and mitotic cells, while
the mitochondria pattern is in the cytoplasmic compartment, this
mixed pattern can be readily identified. Other mixed patterns,
however, can be more difficult to discriminate accurately. This
is particularly true when the titers of two autoantibodies are
relatively similar or when their cognate antigens are in the same
cell compartment.
A second obvious omission is the failure to cover all known
patterns or even all patterns that are already included in the
Brazilian ANA consensus and in other similar initiatives (12).
One may consider that it should be simple to adapt all known
patterns described previously. However, the general focus of the
ICAP is to include patterns that are more clinically relevant and
obtain consensual approval of all participating experts. Rare pat-
terns are excluded at this time; for example, cell cycle patterns
including SG2NA/striatin (52), cyclin B1 (53), heterochromatin
protein 1-beta (54), andM-phase phosphoproteinMPP1 (55), and
EEA1 and other endosomal antigens (34, 56). It is acknowledged
that there may be potential biases and not all patterns can be
equally well justified for their inclusion/exclusion in this first
edition of the ICAP. It is expected that a progressive maturation
process occurs along the successive ICAP editions with a broad
participation of the international community.
It also became clear that the CDC/IUIS ANA Reference Stan-
dards require reevaluation using contemporary ANA IIF and
related technologies. In particular, it is important to clarify anti-
Ro60 versus anti-Ro52 staining patterns, an issue that was not
explicitly discussed in relation to the CDC/IUIS ANA standards.
The CDC/IUIS ANA standard #07 reference serum for human
antibodies to SS-A/Ro was established and released in May 1983
(4). The distinction of Ro52 and Ro60 was not reported until
1988 (57). At this time, there is no CDC/IUIS ANA reference
standard for Ro60 alone or Ro52 alone. Other investigators have
analyzed many of the CDC/IUIS ANA standards for reactivity to
Ro60 and Ro52 and showed that (1) CDC/IUIS ANA standard
#07 has strong reactivity to Ro60 and weak reactivity to Ro52, (2)
CDC/IUIS ANA standard #02 (anti-SS-B/La) and #03 (Speckled)
also have strong anti-Ro60 and weak anti-Ro52 reactivity, and (3)
CDC/IUIS ANA standard #10 (anti-Jo-1) had strong additional
reactivity to Ro52 (58). The current interpretation is that the
subcellular localization of the majority of subcellular Ro60 and
Ro52 are likely different. Anti-Ro60 shows a typical nuclear fine
speckled pattern (AC-4), while anti-Ro52 does not show nuclear
staining (59). In fact,manymonospecific anti-Ro52 donot have an
identifiable staining pattern. There have also been concerns that
not all anti-Ro antibodies give nuclear staining and that may be
explained in part from the autoantibody titer, presence of other
autoantibodies that may interfere, and/or the use of certain brand
of ANA slide substrates that are known not to detect anti-Ro as
nuclear pattern.
In summary, in this first ICAP consensus, we present a clas-
sification tree for ANA with alpha-numeric AC code for each
pattern. The classification includes not only nuclear patterns
but also cytoplasmic and mitotic patterns that are all consid-
ered to be ANA positive. This is an important point deviating
from certain norms in ANA reporting in some clinical immunol-
ogy laboratories that only “clinically relevant” ANA patterns are
reported, while other “less important” patterns are ignored. We
argue that all known patterns should be reported and clinical
relevance acknowledged accordingly. The main concern with
selective reporting, as it is practiced currently in some labora-
tories, is that it promotes hiding information and that poten-
tially can be more harmful. Within the classification tree devel-
oped here, a distinction is made between competent-level and
expert-level patterns based on clinical relevance and/or easiness
of recognition. The goal is to promote a stepwise integration of
ANA reporting to a higher level with continuing training. Future
ICAP editions are expected to further delineate this consensus,
resulting in widely embraced standardization of ANA testing and
reporting.
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